Science Resources RSS Feeds
|
 |
 |
 |
Trastuzumab Current Events | Trastuzumab News
|
|
|
Sort By:
Page Views | Date |
Analysis confirms benefits of combining trastuzumab and chemotherapy
A recent meta-analysis of five major breast cancer trials has confirmed that combination treatment with the antibody trastuzumab and chemotherapy improves survival in women with operable HER-2 positive breast cancer. view more (2007-07-09)
Information about the use and accuracy of breast cancer tests is lacking, study finds
A new study finds that there is little information available about the use of new testing technologies and targeted therapies in breast cancer, specifically the anti-cancer drug trastuzumab (Herceptin). view more (2009-09-14)
Herceptin and chemo improves response rates without major adverse effects in HER2 breast cancer
Women with a particularly aggressive form of breast cancer seem to do better if they are treated with a combined anthracycline and taxane chemotherapy regimen before surgery, together with trastuzumab (Herceptin) before and after surgery, according to results from the largest multi-centre trial to investigate this treatment. view more (2008-04-18)
Small molecule inhibitor shows promise in trastuzumab-resistant metastatic breast cancer
Fox Chase Cancer Center researchers report that a combination of trastuzumab and neratinib (HKI-272) a novel small molecule inhibitor of the HER2 receptor (ErbB2) appears active in women with HER2-positive metastatic breast cancer who have progressed on previous trastuzumab based therapies. view more (2009-05-29)
Gene patenting -- steep cost for health care and patients
The drug trastuzumab (Herceptin) is used to treat HER2-positive breast cancer (a type of breast cancer that overexpresses the HER2 gene and accounts for about 25% of all breast cancers). view more (2007-05-08)
Results good for HER-2 positive breast cancer patients using trastuzumab
Researchers in the North Central Cancer Treatment Group (NCCTG) have shown that patients who receive trastuzumab at the same time as post-chemotherapy radiation treatments for HER-2 positive breast cancer have no more risk for major side effects or complications than those who do not receive the drug. view more (2006-06-06)
Herceptin gives disappointing results in lung cancer trial
Trastuzumab (Herceptin) - a treatment that has increased survival in many breast cancer patients - has failed to live up to hopes that it might also help lung cancer patients. view more (2004-01-08)
Mayo Clinic reports breakthrough treatment for breast cancer
In a joint paper, co-authored by Mayo Clinic's Edith Perez, M.D., and Edward Romond, M.D., of the National Surgical Adjuvant Breast and Bowel Project (NSABP), researchers report complete and combined results of two trials comparing adjuvant chemotherapy with or without concurrent trastuzumab treatment in women with surgically removed HER2-positive... view more... (2005-10-20)
A search for protection against chemotherapy cardiotoxicity
Researchers at the University of Grenoble, in France, have discovered that erythropoietin administration prevents acute cardiotoxic effects induced by doxorubicin and trastuzumab exposures. view more (2007-12-21)
Headlines about Herceptin show equality of access to costly drugs must be tackled
The recent press coverage on the use of Herceptin (brand name for the drug trastuzumab) for treating breast cancer in its early stages shows that issues of equal access to costly but effective drugs must be confronted, says an editorial in this week's BMJ. view more (2005-11-04)
Study suggests newer breast cancer drug may protect heart
By uncovering how one breast cancer drug protects the heart and another does not, Duke University Medical Center researchers believe they may have opened up a new way to screen drugs for possible heart-related side effects and to develop new drugs. view more (2007-06-11)
Herceptin effective in breast cancer cells with low HER-2 levels
Northwestern University and Evanston Northwestern Healthcare researchers have discovered that the monoclonal antibody Herceptin (trastuzumab) used in combination with certain cancer chemotherapies effectively treats breast cancer tumors that produce low or undetectable amounts of the HER-2 oncogene but overexpress the growth factor heregulin... view more... (2006-08-11)
Triple drug combination is promising option to treat metastatic HER2+ breast cancer
Combining two chemotherapy drugs with trastuzumab (Herceptin) to treat women who have metastatic HER2+ breast cancer may offer physicians another choice in their treatment options. view more (2009-05-15)
Fresh use of targeted therapy advances treatment of early HER2-positive breast cancer
The news that the world's first targeted therapy, trastuzumab (Herceptin), is now available for many women with early-stage HER2-positive breast cancer "highlights a truly significant advance in the management of breast cancer," says Edith Perez, M.D., director of Mayo Clinic's Breast Clinic in Jacksonville, Fla. view more (2006-11-20)
New study of targeted therapies for breast cancer -- model for global clinical trials
Two targeted medications designed to treat an aggressive form of breast cancer are being tested in a new study involving 8,000 participants in 50 countries across six continents -- a clinical trial that investigators hope will provide a new model for global cancer research. view more (2008-02-29)
Cancerous vs. healthy cells: Researchers identify the road to success
Conventional cancer treatments are generally effective in wiping out tumor cells, but in the process they also may kill healthy cells. view more (2006-04-10)
Reining in cancer - first laboratory study to show that combining novel targeted therapiesmay keep cancer cells under control
A team of Italian researchers has demonstrated in the laboratory for the first time that combining two of the newest anti-cancer targeted agents may produce a powerful new combination against breast cancer - and possibly many other cancers as well. Their findings are reported (Thursday 24 January) in the journal Annals of Oncology.* They found... view more... (2002-01-21)
Herceptin treatment lowers recurrence rate in early breast cancer
The targeted drug trastuzumab, or Herceptin, previously shown to prolong survival in advanced breast cancer, dramatically reduced the chances of recurrence in patients with early-stage disease when given for one year following standard chemotherapy. view more (2005-10-20)
New role for sugars: Research shows connections between sugar modifications in cells and cancer
In a ground-breaking study published in the top journal, Cell, Dr. James Dennis, senior investigator at the Samuel Lunenfeld Research Institute at Mount Sinai Hospital, has discovered a new role for sugars on proteins. view more (2007-04-06)
HER2 levels may aid in treatment selection for metastatic breast cancer
Findings published in the December 1, 2008, issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, show lapatinib benefits women with HER2-positive breast cancer, while women with HER2-negative breast cancer or those who express EGRF alone derive no incremental benefit. view more (2008-12-03)
|
|
|
|
Sort By:
Page Views | Date |
|
|
